478375-42-7

Basic information

• Product Name: Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate
• Synonyms: 3-(2-Methoxy-2-oxoethyl)phenylboronic acid, pinacol ester;Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate;3-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl-acetic acid Methyl ester;Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 478375-42-7
• Molecular Formula: C₁₅H₂₁BO₄
• Molecular Weight: 276.13584
• Mol File: 478375-42-7.mol

Chemical Properties

• Boiling Point: 372.043 °C at 760 mmHg
• Flash Point: 178.806 °C
• Appearance: /
• Density: 1.075 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate(478375-42-7)
• EPA Substance Registry System: Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate(478375-42-7)

Safety Data

• Hazardous Substances Data: 478375-42-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate is used as a synthetic intermediate for the development of pharmaceutical compounds. Its reactivity in cross-coupling reactions allows for the creation of complex molecular structures that are essential in the synthesis of new drugs.
Used in Material Science:
Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate is used as a building block in the synthesis of advanced materials. Its boronate functional group enables the formation of new chemical bonds, which can be utilized to create materials with unique properties for various applications in material science.

Upstream product

• 1878-67-7 3-Bromophenylacetic acid 
• 67-56-1 methanol 
• 396131-82-1 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetonitrile 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 42058-59-3 3-hydroxy-benzeneacetic acid, methyl ester 
• 621-37-4 m-hydroxyphenylacetic acid 
• 73183-34-3 bis(pinacol)diborane 
• 147283-87-2 methyl [3-[[(trifluoromethyl)sulfonyl]oxy]phenyl]-acetate 

Downstream Products

• 849931-42-6 (3-{5-[5-cyano-1-(2,4-difluoro-benzyl)-6-oxo-4-trifluoromethyl-1,6-dihydro-pyridin-2-yl]-thiophen-3-yl}-phenyl)-acetic acid methyl ester 
• 934176-82-6 (5-{2-[2-(2',3',4'-trimethoxy-biphenyl-3-yl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid 
• 934176-81-5 (5-{2-[2-(2',3',4'-trimethoxy-biphenyl-3-yl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 597584-94-6 methyl 3-cyclopropyl-2-[4'-(4-methylpiperazin-1-yl)-1,1'-biphenyl-3-yl]propanoate 
• 597584-91-3 methyl 2-[4'-(4-methylpiperazin-1-yl)-1,1'-biphenyl-3-yl]-3-phenylpropanoate 
• 597584-97-9 methyl 3-cyclobutyl-2-[4'-(4-methylpiperazin-1-yl)-1,1'-biphenyl-3-yl]propanoate 
• 1017233-77-0 (+)-pinanediol 3-(methoxycarbonylmethyl)phenylboronate 
• 1201930-28-0 [3-(5-bromopyrimidin-2-yl)phenyl]acetic acid 
• 1201930-30-4 [3-(5-bromopyrimidin-2-yl)phenyl]acetohydrazide 
• 1363569-11-2 3-{3-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzyl}-1,2,4-triazolo[4,3-b]pyridazine-6-carboxylic acid 
• 1231994-88-9 methyl 3-[3-(5-bromopyrimidin-2-yl)benzyl]-1,2,4-triazolo[4,3-b]pyridazine-6-carboxylate 
• 1231994-89-0 butyl 3-[3-(5-bromopyrimidin-2-yl)benzyl]-1,2,4-triazolo[4,3-b]pyridazine-6-carboxylate 
• 1231994-90-3 3-[3-(5-bromopyrimidin-2-yl)benzyl]-1,2,4-triazolo[4,3-b]-pyridazine-6-carboxylic acid 
• 1231994-91-4 N-methyl-3-[3-(5-bromopyrimidin-2-yl)benzyl]-1,2,4-triazolo[4,3-b]pyridazine-6-carboxamide 

Relevant articles and documents

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives

Compounds of the formula I, in which R1, R2, R3, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the t

3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives

Compounds of the formula (I), in which R1, R2, R3, R3′, R4 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for th

Rational design of phosphoinositide 3-kinase inhibitors that exhibit selectivity over the phosphoinositide 3-kinase isoform

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.

3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors

New pyridazin-3(2H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).